NASDAQ:IMVTImmunovant Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immunovant Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.20 -1.01 (-6.64 %) (As of 04/5/2020 01:42 PM ET) Add Compare Share Today's Range$13.86Now: $14.20▼$15.6350-Day Range$8.36MA: $14.28▼$17.0452-Week Range$8.34Now: $14.20▼$18.69Volume137,660 shsAverage Volume193,428 shsMarket Capitalization$772.48 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody targeting the neonatal Fc receptor, which is in phase II clinical trial for the treatment of myasthenia gravis and graves' ophthalmopathy. The company was formerly known as Health Sciences Acquisitions Corporation and changed its name to Immunovant, Inc. in December 2019. Immunovant, Inc. was incorporated in 2018 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.20, Immunovant has a potential upside of 77.5% from its current price of $14.20.Amount of Analyst CoverageImmunovant has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.4 Community Rank Outperform VotesImmunovant has received 15 “outperform” votes. (Add your “outperform” vote.)Underperform VotesImmunovant has received 7 “underperform” votes. (Add your “underperform” vote.)Community SentimentImmunovant has received 68.18% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Immunovant and other stocks. Vote “Outperform” if you believe IMVT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMVT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 20.83% of the stock of Immunovant is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Immunovant are expected to grow by 31.93% in the coming year, from ($1.19) to ($1.57) per share. Previous Next Analyst Opinion: 4.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.83 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Holding & other investment offices Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMVT Previous Symbol CUSIPN/A CIKN/A Webhttp://www.immunovant.com/ Phone917-580-3099Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees17 Outstanding Shares54,400,000Market Cap$772.48 million Next Earnings Date5/8/2020 (Estimated) OptionableNot Optionable Receive IMVT News and Ratings via Email Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:IMVT Rates by TradingView Immunovant (NASDAQ:IMVT) Frequently Asked Questions How has Immunovant's stock been impacted by COVID-19 (Coronavirus)? Immunovant's stock was trading at $14.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IMVT stock has increased by 0.4% and is now trading at $14.20. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Immunovant? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Immunovant. When is Immunovant's next earnings date? Immunovant is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Immunovant. How were Immunovant's earnings last quarter? Immunovant (NASDAQ:IMVT) released its quarterly earnings results on Friday, February, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.03. View Immunovant's earnings history. What price target have analysts set for IMVT? 5 brokers have issued 1 year target prices for Immunovant's stock. Their forecasts range from $21.00 to $30.00. On average, they anticipate Immunovant's stock price to reach $25.20 in the next year. This suggests a possible upside of 77.5% from the stock's current price. View analysts' price targets for Immunovant. Has Immunovant been receiving favorable news coverage? News headlines about IMVT stock have trended very negative recently, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Immunovant earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutImmunovant. Are investors shorting Immunovant? Immunovant saw a increase in short interest in March. As of March 13th, there was short interest totaling 813,900 shares, an increase of 8.8% from the February 27th total of 747,900 shares. Based on an average daily volume of 110,800 shares, the short-interest ratio is currently 7.3 days. Approximately 16.7% of the shares of the company are short sold. View Immunovant's Current Options Chain. Who are some of Immunovant's key competitors? Some companies that are related to Immunovant include Vivint Smart Home (VVNT), Verra Mobility (VRRM), AdaptHealth (AHCO), GS ACQUISITION /SH CL A (GSAH), HAYMAKER ACQUIS/SH CL A (HYAC), Bain Capital Specialty Finance (BCSF), Global Cord Blood (CO), Gores Holdings III (GRSH), Crescent Capital BDC (CCAP), FORUM MERGER II/SH CL A (FMCI), Andina Acquisition Corp. III (AMCI), New Frontier Health (NFH), Grid Dynamics (GDYN), ANDINA ACQUISIT/SH SH (ANDA) and Kaleyra (KLR). What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Repligen (RGEN), Paypal (PYPL), PPD (PPD), Progyny (PGNY), Passage Bio (PASG), InMode (INMD), INmune Bio (INMB), Interpace Diagnostics Group (IDXG), Cabaletta Bio (CABA) and I-Mab (BDTX). Who are Immunovant's key executives? Immunovant's management team includes the following people: Dr. Peter Salzmann M.B.A., M.D., CEO & DirectorMs. Pamela Yanchik Connealy M.B.A., Chief Financial OfficerDr. Sandeep C. Kulkarni, Chief Operating OfficerDr. Julia G. Butchko Ph.D., Chief Devel. & Technology OfficerMr. W. Bradford Middlekauff, Gen. Counsel (Age 58) What is Immunovant's stock symbol? Immunovant trades on the NASDAQ under the ticker symbol "IMVT." How do I buy shares of Immunovant? Shares of IMVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Immunovant's stock price today? One share of IMVT stock can currently be purchased for approximately $14.20. How big of a company is Immunovant? Immunovant has a market capitalization of $772.48 million. Immunovant employs 17 workers across the globe. View additional information about Immunovant. What is Immunovant's official website? The official website for Immunovant is http://www.immunovant.com/. How can I contact Immunovant? Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK 10, 10018. The company can be reached via phone at 917-580-3099. This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: Hedge Funds - Risk or Reward?
